+

WO2008034117A3 - Methods for using soy peptides to inhibit h3 acetylation, reduce expression of hmg-coa reductase and increase ldl receptor and sp1 expression in a mammal - Google Patents

Methods for using soy peptides to inhibit h3 acetylation, reduce expression of hmg-coa reductase and increase ldl receptor and sp1 expression in a mammal Download PDF

Info

Publication number
WO2008034117A3
WO2008034117A3 PCT/US2007/078585 US2007078585W WO2008034117A3 WO 2008034117 A3 WO2008034117 A3 WO 2008034117A3 US 2007078585 W US2007078585 W US 2007078585W WO 2008034117 A3 WO2008034117 A3 WO 2008034117A3
Authority
WO
WIPO (PCT)
Prior art keywords
expression
hmg
acetylation
mammal
inhibit
Prior art date
Application number
PCT/US2007/078585
Other languages
French (fr)
Other versions
WO2008034117A2 (en
Inventor
Alfredo Flores Galvez
Original Assignee
Alfredo Flores Galvez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/532,528 external-priority patent/US7731995B2/en
Application filed by Alfredo Flores Galvez filed Critical Alfredo Flores Galvez
Publication of WO2008034117A2 publication Critical patent/WO2008034117A2/en
Publication of WO2008034117A3 publication Critical patent/WO2008034117A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Controlled studies demonstrate that methods using soy related peptides inhibit H3 acetylation, reduce expression of HMG-CoA reductase and increase LDL receptor and Sp1 expression in mammals. The present disclosure is generally directed to using lunasin peptides and/or lunasin peptide derivatives to 1) inhibit H3 acetylation, 2) reduce expression of HMG-CoA reductase, 3) increase LDL receptor expression or 4) increase Sp1 expression in a mammal. In at least one exemplary embodiment of the present disclosure, an effective amount of lunasin peptides or lunasin peptide derivatives and one or more enzyme inhibitors is provided to a mammal to 1) inhibit H3 acetylation, 2) reduce expression of HMG-CoA reductase, 3) increase LDL receptor expression or 4) increase Sp1 expression in a mammal.
PCT/US2007/078585 2006-09-16 2007-09-15 Methods for using soy peptides to inhibit h3 acetylation, reduce expression of hmg-coa reductase and increase ldl receptor and sp1 expression in a mammal WO2008034117A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96652906P 2006-09-16 2006-09-16
US11/532,528 2006-09-16
US11/532,528 US7731995B2 (en) 2006-09-16 2006-09-16 Methods for using soy peptides to inhibit H3 acetylation, reduce expression of HMG CoA reductase, and increase LDL receptor and Sp1 expression in a mammal
US60/966,529 2006-09-16

Publications (2)

Publication Number Publication Date
WO2008034117A2 WO2008034117A2 (en) 2008-03-20
WO2008034117A3 true WO2008034117A3 (en) 2008-06-05

Family

ID=39184637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078585 WO2008034117A2 (en) 2006-09-16 2007-09-15 Methods for using soy peptides to inhibit h3 acetylation, reduce expression of hmg-coa reductase and increase ldl receptor and sp1 expression in a mammal

Country Status (1)

Country Link
WO (1) WO2008034117A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072784A2 (en) * 2000-03-24 2001-10-04 Filgen Biosciences, Inc. Peptides binding to non-acetylated h3 and h4 histones for cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072784A2 (en) * 2000-03-24 2001-10-04 Filgen Biosciences, Inc. Peptides binding to non-acetylated h3 and h4 histones for cancer therapy

Also Published As

Publication number Publication date
WO2008034117A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2006138238A3 (en) Methods of protecting against apoptosis using lipopeptides
WO2010060937A3 (en) Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
WO2007056681A3 (en) Methods for administering hypoglycemic agents
WO2007008684A3 (en) Ligands of melanocortin receptors
WO2005117943A3 (en) Biomarkers for monitoring inhibition of impdh pathway
AU2007299726A8 (en) Combination comprising an HMG-CoA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
WO2006078752A3 (en) Inhibitors of dna methyltransferase
WO2007081755A3 (en) Indole-benzimidazole and indazole inhibitors of tyrosine phosphatases
WO2007090384A3 (en) Adhesives and adhesive methods
AU2007306104A1 (en) Hydrobenzamide derivatives as inhibitors of Hsp90
WO2009133374A3 (en) Antisapstain compositions comprising a haloalkynyl compound, an azole and an unsaturated acid
WO2008076427A3 (en) Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
WO2007109037A3 (en) Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
WO2006132959A3 (en) Inhibition of thrombin generation
WO2010066639A3 (en) Skin lightening compositions with acetylcholinesterase inhibitors
WO2007019526A3 (en) Compositions and methods for controlling glucose and lipid uptake from foods
MX2009013982A (en) Compositions comprising tryptophan hydroxylase inhibitors.
WO2010081143A3 (en) Cymbal mounting assembly
AU2007259257A8 (en) Antitumoral dihydropyran-2-one compounds
WO2007079916A3 (en) Combination of triazine derivatives and hmg- coa reductase inhibitors for the treatment of diabetes
WO2007146445A3 (en) Individualized pharmaceutical selection and packaging
WO2007095250A3 (en) Compositions and methods for inhibiting optic nerve damage
WO2006069719A3 (en) Lyophilization of virosomes
WO2006117761A3 (en) Magnesium salts of hmg-coa reductase inhibitors
WO2006023866A3 (en) Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07842568

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07842568

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载